All In Biotech

Drug Trial Radar · NCT07795567

A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Ivermectin Cream 1% (Taro Pharmaceutical Industries, Inc.) To Soolantra™ Cream 1% (US Reference Listed Drug), PrRosiver® Cream 1% (Canadian Reference Product), and Each Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 865 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

865

Actual

Start

Dec 9, 2025

Primary completion

Jun 24, 2026

Study completion Jun 24, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate and demonstrate the therapeutic equivalence and safety of Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1% \& to Placebo for the treatment of moderate to severe facial rosacea.

Conditions

  • Rosacea

Interventions

  • Ivermectin Cream 1%Drug

    The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.

  • Soolantra™ Cream 1%Drug

    The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.

  • PrRosiver® Cream 1%Drug

    The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.

  • Placebo ControlDrug

    The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate & evaluate the therapeutic, equivalence, and safety of the investigational productTime frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Pharmaceutical Industries, Inc.

    Hawthorne, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.